The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Spermine and Citrate as Metabolic Biomarkers for Assessing Prostate Cancer Aggressiveness
Open accessAbstract
Separating indolent from aggressive prostate cancer is an important clinical challenge for identifying patients eligible for active surveillance, thereby reducing the risk of overtreatment. The purpose of this study was to assess prostate cancer aggressiveness by metabolic profiling of prostatectomy tissue and to identify specific metabolites as biomarkers for aggressiveness. Prostate tissue samples (n = 158, 48 patients) with a high cancer content (mean: 61.8%) were obtained using a new harvesting method, and metabolic profiles of samples representing different Gleason scores (GS) were acquired by high resolution magic angle spinning magnetic resonance spectroscopy (HR-MAS). Multivariate analysis (PLS, PLS-DA) and absolute quantification (LCModel) were used to examine the ability to predict cancer aggressiveness by comparing low grade (GS = 6, n = 30) and high grade (GS≥7, n = 81) cancer with normal adjacent tissue (n = 47). High grade cancer tissue was distinguished from low grade cancer tissue by decreased concentrations of spermine (p = 0.0044) and citrate (p = 7.73·10(-4)), and an increase in the clinically applied (total choline+creatine+polyamines)/citrate (CCP/C) ratio (p = 2.17·10(-4)). The metabolic profiles were significantly correlated to the GS obtained from each tissue sample (r = 0.71), and cancer tissue could be distinguished from normal tissue with sensitivity 86.9% and specificity 85.2%. Overall, our findings show that metabolic profiling can separate aggressive from indolent prostate cancer. This holds promise for the benefit of applying in vivo magnetic resonance spectroscopy (MRS) within clinical MR imaging investigations, and HR-MAS analysis of transrectal ultrasound-guided biopsies has a potential as an additional diagnostic tool.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PLS-regression: a basic tool of chemometrics
Wold, S., Sjöström, M., & Eriksson, L. (2001) · Chemometrics and Intelligent Laboratory Systems · doi:10.1016/s0169-7439(01)00155-1 · Cited by 10,084 · cited 4×
“When dividing the samples into normal, high grade (GS$7) and low grade (GS = 6), correct classification by PLS-DA was 85.8% (sensitivity 89.3%, specificity 82.3%), 77.4% (sensitivity 84.4%, specificity 70.5%), and 65.8% (sensitivity 64.1%, specificity 67.6%), respectively.”
MethodInfluentialAssessment of PLSDA Cross Validation
Westerhuis, J. A., Hoefsloot, H. C. J., Smit, S., Vis, D. J., Smilde, A. K., van Velzen, E. J. J., van Duijnhoven, J. P. M., & van Dorsten, F. A. (2008) · Metabolomics · doi:10.1007/s11306-007-0099-6 · Cited by 1,471
Cited by
Polyamine metabolism and cancer: treatments, challenges and opportunities
Casero, R. A., Murray Stewart, T., & Pegg, A. E. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0050-3 · Cited by 817
The Need for Multi-Omics Biomarker Signatures in Precision Medicine
Olivier, M., Asmis, R., Hawkins, G. A., Howard, T. D., & Cox, L. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194781 · Cited by 499
Lemaître, G., Martí, R., Freixenet, J., Vilanova, J. C., Walker, P. M., & Meriaudeau, F. (2015) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2015.02.009 · Cited by 348
A landscape of metabolic variation across tumor types
Reznik, E., Luna, A., Aksoy, B. A., Liu, E. M., La, K., Ostrovnaya, I., Creighton, C. J., Hakimi, A. A., & Sander, C. (2018) · Cell Systems · doi:10.1016/j.cels.2017.12.014 · Cited by 172
Metadata
- Authors
- Giskeødegård, G. F., Bertilsson, H., Selnæs, K. M., Wright, A. J., Bathen, T. F., Viset, T., Halgunset, J., Angelsen, A., Gribbestad, I. S., & Tessem, M.-B.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-04-23
- Volume
- 8
- Issue
- 4
- Pages
- e62375
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2096873313
- Cited by
- 182
- References
- 2
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.